SI2931752T1 - Zdravljenje bolezenskih celic CD47+ s fuzijami ALFA-FC SIRP - Google Patents
Zdravljenje bolezenskih celic CD47+ s fuzijami ALFA-FC SIRPInfo
- Publication number
- SI2931752T1 SI2931752T1 SI201331610T SI201331610T SI2931752T1 SI 2931752 T1 SI2931752 T1 SI 2931752T1 SI 201331610 T SI201331610 T SI 201331610T SI 201331610 T SI201331610 T SI 201331610T SI 2931752 T1 SI2931752 T1 SI 2931752T1
- Authority
- SI
- Slovenia
- Prior art keywords
- fusions
- treatment
- disease cells
- sirp alpha
- sirp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738008P | 2012-12-17 | 2012-12-17 | |
| EP13865442.1A EP2931752B1 (en) | 2012-12-17 | 2013-12-17 | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
| PCT/CA2013/001046 WO2014094122A1 (en) | 2012-12-17 | 2013-12-17 | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2931752T1 true SI2931752T1 (sl) | 2019-12-31 |
Family
ID=50977456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201331610T SI2931752T1 (sl) | 2012-12-17 | 2013-12-17 | Zdravljenje bolezenskih celic CD47+ s fuzijami ALFA-FC SIRP |
| SI201331996T SI3575326T1 (sl) | 2012-12-17 | 2013-12-17 | Zdravljenje bolnih celic CD47 s fuzijo SIRP ALFA FC |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201331996T SI3575326T1 (sl) | 2012-12-17 | 2013-12-17 | Zdravljenje bolnih celic CD47 s fuzijo SIRP ALFA FC |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9969789B2 (sl) |
| EP (3) | EP4116331A1 (sl) |
| JP (3) | JP6335189B2 (sl) |
| CN (2) | CN110066341B (sl) |
| AU (4) | AU2013362789B8 (sl) |
| CA (2) | CA2894245C (sl) |
| CY (1) | CY1122463T1 (sl) |
| DK (2) | DK2931752T3 (sl) |
| ES (2) | ES2914814T3 (sl) |
| HK (1) | HK1217716A1 (sl) |
| HR (1) | HRP20192013T1 (sl) |
| HU (2) | HUE047221T2 (sl) |
| LT (1) | LT2931752T (sl) |
| ME (1) | ME03550B (sl) |
| PL (2) | PL2931752T3 (sl) |
| PT (2) | PT3575326T (sl) |
| RS (1) | RS59591B1 (sl) |
| SI (2) | SI2931752T1 (sl) |
| WO (1) | WO2014094122A1 (sl) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2429574B1 (en) | 2009-05-15 | 2015-05-06 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp - cd47 interaction |
| AU2013362789B8 (en) * | 2012-12-17 | 2018-08-02 | Pfizer Inc. | Treatment of CD47+ disease cells with SIRP Alpha-Fc fusions |
| TWI702228B (zh) * | 2014-08-08 | 2020-08-21 | 美商Ａｌｘ腫瘤技術股份有限公司 | 信號調節蛋白α（ｓｉｇｎａｌ-ｒｅｇｕｌａｔｏｒｙ ｐｒｏｔｅｉｎ α， ＳＩＲＰ-α）變體構築物及其用途 |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| CA2994927A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| EP3180363B2 (en) | 2014-08-15 | 2022-09-14 | Merck Patent GmbH | Sirp-alpha immunoglobulin fusion proteins |
| CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| IL274151B (en) | 2015-05-21 | 2022-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| BR102016018074A2 (pt) * | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
| CN108350048B (zh) | 2015-08-07 | 2024-02-09 | Alx肿瘤生物技术公司 | 具有SIRP-α结构域或其变体的构建体 |
| BR112018006578A2 (pt) | 2015-10-01 | 2018-12-26 | Heat Biologics, Inc. | composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas |
| US10927173B2 (en) | 2016-01-11 | 2021-02-23 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
| CN107149682B (zh) * | 2016-03-04 | 2022-01-04 | 复旦大学 | 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法 |
| CA3020026A1 (en) * | 2016-04-15 | 2017-10-19 | Trillium Therapeutics Inc. | Macrophage stimulation in cd47 blockade therapy |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| WO2018012952A1 (ko) * | 2016-07-15 | 2018-01-18 | 한국과학기술연구원 | 신규 나노케이지 및 그의 용도 |
| JP7241677B2 (ja) * | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ４７併用療法 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3532497B1 (en) * | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| US11779631B2 (en) | 2016-11-03 | 2023-10-10 | Pfizer Inc. | CD47 blockade therapy by HDAC inhibitors |
| EP3534964A4 (en) | 2016-11-03 | 2020-07-15 | Trillium Therapeutics Inc. | IMPROVEMENT OF CD47 BLOCKING THERAPY BY PROTEASOME INHIBITORS |
| EP3563835A4 (en) * | 2016-12-29 | 2020-12-30 | Korea Institute of Science and Technology | NEW EXOSOME-BASED ANTI-CANCER AGENT |
| CN108277234A (zh) * | 2017-01-05 | 2018-07-13 | 上海白泽生物科技有限公司 | 封闭cd47并激发抗肿瘤免疫的重组溶瘤腺病毒及其用途 |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| EP3585409A4 (en) | 2017-02-27 | 2020-12-02 | Shattuck Labs, Inc. | CHEMERICAL PROTEINS BASED ON CSF1R |
| CN110290798B (zh) | 2017-02-27 | 2024-04-05 | 沙塔克实验室有限公司 | 基于vsig8的嵌合蛋白 |
| US11332509B2 (en) | 2017-02-27 | 2022-05-17 | Shattuck Labs, Inc. | Methods of making and using extracellular domain-based chimeric proteins |
| WO2018176132A1 (en) * | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
| CN113831417B (zh) * | 2017-05-08 | 2024-10-01 | 上海津曼特生物科技有限公司 | 双特异性重组蛋白及其应用 |
| BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
| KR102646468B1 (ko) | 2017-08-02 | 2024-03-11 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd47 항체 및 이의 용도 |
| CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| WO2019066536A1 (ko) * | 2017-09-28 | 2019-04-04 | 한국과학기술연구원 | 신규 암 치료용 조성물 |
| CN111465612B (zh) | 2017-10-13 | 2024-08-27 | 哈普恩治疗公司 | B细胞成熟抗原结合蛋白 |
| CA3080640C (en) * | 2017-11-06 | 2024-04-09 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
| AU2017439776A1 (en) | 2017-11-20 | 2020-06-04 | Taizhou Mabtech Pharmaceutical Co., Ltd | Bifunctional fusion protein targeting CD47 and PD-l1 |
| EP3752190B1 (en) | 2018-02-12 | 2022-07-06 | Forty Seven, Inc. | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies |
| CN108484774B (zh) * | 2018-03-09 | 2021-11-05 | 上海高菲生物科技有限公司 | 一种SIRPα融合蛋白及其制备方法和用途 |
| CA3093603A1 (en) * | 2018-03-13 | 2019-09-19 | Trillium Therapeutics Inc. | Cd47 blockade therapy and cd38 antibody |
| US20210040219A1 (en) * | 2018-03-13 | 2021-02-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by egfr antibody |
| KR20200133376A (ko) | 2018-03-21 | 2020-11-27 | 알렉소 온콜로지 인크. | 신호-조절 단백질 알파에 대한 항체 및 사용 방법 |
| CN110305212A (zh) | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| CN110386984B (zh) * | 2018-04-17 | 2022-04-22 | 杭州尚健生物技术有限公司 | 结合cd47蛋白的融合蛋白及其应用 |
| CN108794641A (zh) * | 2018-07-04 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种针对EGFRvIII的多功能融合蛋白及其应用 |
| KR20210030267A (ko) | 2018-07-10 | 2021-03-17 | 고쿠리츠다이가쿠호진 고베다이가쿠 | 항 SIRPα 항체 |
| EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES |
| WO2020047319A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| WO2020047326A2 (en) | 2018-08-31 | 2020-03-05 | ALX Oncology Inc. | Decoy polypeptides |
| US20210315864A1 (en) * | 2018-09-04 | 2021-10-14 | Trillium Therapeutics Inc. | Cd47 blockade with parp inhibition for disease treatment |
| IL297931B1 (en) | 2018-09-25 | 2024-11-01 | Harpoon Therapeutics Inc | DLL3 binding proteins and methods of use |
| EP3880215A4 (en) * | 2018-11-13 | 2023-02-15 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER |
| CN109517054B (zh) * | 2018-12-04 | 2022-04-08 | 江苏东抗生物医药科技有限公司 | SIRPα变体或其融合蛋白及其应用 |
| EP3936526A4 (en) | 2019-03-06 | 2023-03-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE |
| MA56045A (fr) | 2019-05-31 | 2022-04-06 | Alx Oncology Inc | Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| EP4065101A1 (en) | 2019-11-27 | 2022-10-05 | ALX Oncology Inc. | Combination therapies for treating cancer |
| CN111253482B (zh) * | 2020-02-18 | 2021-11-30 | 中国人民解放军军事科学院军事医学研究院 | SIRPa变体、融合蛋白、及其应用 |
| JP2023528341A (ja) | 2020-06-01 | 2023-07-04 | エーエルエックス オンコロジー インコーポレイテッド | 低メチル化剤を含むがんを治療するための併用療法 |
| WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| CU20230001A7 (es) | 2020-07-07 | 2023-09-07 | BioNTech SE | Arn terapéutico para el cáncer positivo para vph |
| CN114057888A (zh) * | 2020-07-30 | 2022-02-18 | 三生国健药业（上海）股份有限公司 | 一种SIRPα-Fc融合蛋白 |
| EP4232052A1 (en) * | 2020-10-22 | 2023-08-30 | Actinium Pharmaceuticals, Inc. | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4256336A1 (en) | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| EP4329520A1 (en) | 2021-04-27 | 2024-03-06 | Pfizer Inc. | Enhancement of cd47 blockade therapy with dhfr inhibitors |
| WO2022241157A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| WO2023006390A1 (en) * | 2021-07-30 | 2023-02-02 | Ludwig-Maximilians-Universität München | Mesothelin antibodies and use thereof |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023073580A1 (en) | 2021-10-29 | 2023-05-04 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| WO2023079438A1 (en) | 2021-11-08 | 2023-05-11 | Pfizer Inc. | Enhancement of cd47 blockade therapy with anti-vegf agents |
| JP2024540448A (ja) | 2021-11-19 | 2024-10-31 | ケーアイエスティー（コリア インスティテュート オブ サイエンス アンド テクノロジー） | 標的細胞への医薬品有効成分の赤血球媒介送達のための治療化合物 |
| WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| CA3236718A1 (en) * | 2021-12-21 | 2023-06-29 | Fbd Biologics Limited | Engineered sirp.alpha. variants and methods of use thereof |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023183890A1 (en) | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Multivalent sirp-alpha fusion polypeptides |
| US20230365648A1 (en) | 2022-03-24 | 2023-11-16 | Bitterroot Bio, Inc. | Sirp-alpha fusion polypeptides with modified fc domains |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400650A (zh) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
| WO2023228044A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Dosing regimens of sirp alpha fusion proteins for treatment of cancer |
| US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| WO2024025264A1 (en) * | 2022-07-24 | 2024-02-01 | Shiftbio Co., Ltd. | Method for treating cancer and inflammatory diseases using stem cell- derived extracellular vesicles comprising sirp |
| WO2024040151A1 (en) | 2022-08-18 | 2024-02-22 | Pfizer Inc. | Sirp alpha fusion protein and anti-cd38 antibody combination therapies |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024121777A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5580756A (en) | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1997048723A2 (en) | 1996-06-17 | 1997-12-24 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Hofgartenstrasse 2 | Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products |
| US7074589B1 (en) * | 1996-06-17 | 2006-07-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acids encoding BDP-1 |
| US6541615B1 (en) | 1996-11-15 | 2003-04-01 | Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. | SIRP proteins and uses thereof |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| EP1244707A1 (de) | 1999-11-30 | 2002-10-02 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper gegen signal-regulator-proteine |
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| US7282556B2 (en) | 2001-05-15 | 2007-10-16 | Emory University | Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47 |
| US6541516B1 (en) | 2001-09-14 | 2003-04-01 | Isp Investments Inc. | Water miscible emulsions of pyrethroid insecticides or triazole fungicides |
| EP1369128A1 (en) | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
| CA2499816C (en) * | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| CN101133083A (zh) | 2003-11-11 | 2008-02-27 | 中外制药株式会社 | 人源化的抗cd47抗体 |
| CA2595904A1 (en) * | 2005-02-01 | 2006-08-10 | Research Development Foundation | Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders |
| NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| AU2007213709A1 (en) | 2006-02-08 | 2007-08-16 | Targeted Molecular Diagnostics, Llc | Bivalent ErbB ligand binding molecules and methods for their preparation and use |
| CA2652570A1 (en) | 2006-05-15 | 2007-11-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2799449A1 (en) | 2006-05-25 | 2014-11-05 | Bayer Intellectual Property GmbH | Dimeric molecular complexes |
| EP2388270A3 (en) * | 2007-10-11 | 2012-04-25 | The Hospital For Sick Children | Modulation of SIRPa - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| US8541543B2 (en) | 2007-11-20 | 2013-09-24 | Academia Sinica | Peptides specific for hepatocellular carcinoma cells and applications thereof |
| DE102007056623B3 (de) | 2007-11-23 | 2009-05-20 | Mtu Friedrichshafen Gmbh | Verfahren zur Regelung eines stationären Gasmotors |
| CA2711370C (en) | 2008-01-15 | 2017-06-13 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| ES2740823T3 (es) | 2008-01-15 | 2020-02-06 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| EA201100947A1 (ru) | 2008-12-19 | 2012-02-28 | Новартис Аг | Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений |
| WO2010083253A2 (en) | 2009-01-14 | 2010-07-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| EP2429574B1 (en) | 2009-05-15 | 2015-05-06 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp - cd47 interaction |
| CN102939303A (zh) | 2009-12-22 | 2013-02-20 | 诺瓦提斯公司 | 四价cd47-抗体恒定区融合蛋白用于治疗 |
| LT3789038T (lt) | 2010-05-14 | 2022-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47 |
| CN103429261A (zh) * | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | 半寿期改进的修饰抗体 |
| US20140242095A1 (en) | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| PL2804617T3 (pl) * | 2012-01-17 | 2020-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Reagenty sirp-alfa o wysokim powinowactwie |
| EP2812443B1 (en) | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| WO2014093678A2 (en) | 2012-12-12 | 2014-06-19 | Frazier William A | Therapeutic cd47 antibodies |
| AU2013362789B8 (en) * | 2012-12-17 | 2018-08-02 | Pfizer Inc. | Treatment of CD47+ disease cells with SIRP Alpha-Fc fusions |
| ES2944477T3 (es) | 2013-02-06 | 2023-06-21 | Inhibrx Inc | Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos |
| EP3188758B1 (en) | 2014-08-08 | 2023-10-04 | The Board of Trustees of the Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| TWI702228B (zh) | 2014-08-08 | 2020-08-21 | 美商Ａｌｘ腫瘤技術股份有限公司 | 信號調節蛋白α（ｓｉｇｎａｌ-ｒｅｇｕｌａｔｏｒｙ ｐｒｏｔｅｉｎ α， ＳＩＲＰ-α）變體構築物及其用途 |
| EP3180363B2 (en) | 2014-08-15 | 2022-09-14 | Merck Patent GmbH | Sirp-alpha immunoglobulin fusion proteins |
| CA3020026A1 (en) | 2016-04-15 | 2017-10-19 | Trillium Therapeutics Inc. | Macrophage stimulation in cd47 blockade therapy |
| WO2018176132A1 (en) | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
-
2013
- 2013-12-17 AU AU2013362789A patent/AU2013362789B8/en active Active
- 2013-12-17 US US14/653,165 patent/US9969789B2/en active Active
- 2013-12-17 EP EP22162692.2A patent/EP4116331A1/en active Pending
- 2013-12-17 CN CN201910261473.XA patent/CN110066341B/zh active Active
- 2013-12-17 SI SI201331610T patent/SI2931752T1/sl unknown
- 2013-12-17 PT PT191851757T patent/PT3575326T/pt unknown
- 2013-12-17 EP EP19185175.7A patent/EP3575326B8/en active Active
- 2013-12-17 SI SI201331996T patent/SI3575326T1/sl unknown
- 2013-12-17 EP EP13865442.1A patent/EP2931752B1/en active Active
- 2013-12-17 HU HUE13865442A patent/HUE047221T2/hu unknown
- 2013-12-17 PL PL13865442T patent/PL2931752T3/pl unknown
- 2013-12-17 JP JP2015548121A patent/JP6335189B2/ja active Active
- 2013-12-17 PL PL19185175T patent/PL3575326T3/pl unknown
- 2013-12-17 ME MEP-2019-310A patent/ME03550B/me unknown
- 2013-12-17 WO PCT/CA2013/001046 patent/WO2014094122A1/en active Application Filing
- 2013-12-17 CA CA2894245A patent/CA2894245C/en active Active
- 2013-12-17 CN CN201380073010.1A patent/CN105073780B/zh active Active
- 2013-12-17 RS RS20191446A patent/RS59591B1/sr unknown
- 2013-12-17 DK DK13865442T patent/DK2931752T3/da active
- 2013-12-17 HU HUE19185175A patent/HUE058790T2/hu unknown
- 2013-12-17 LT LT13865442T patent/LT2931752T/lt unknown
- 2013-12-17 CA CA3145468A patent/CA3145468A1/en active Pending
- 2013-12-17 ES ES19185175T patent/ES2914814T3/es active Active
- 2013-12-17 ES ES13865442T patent/ES2755156T3/es active Active
- 2013-12-17 PT PT138654421T patent/PT2931752T/pt unknown
- 2013-12-17 DK DK19185175.7T patent/DK3575326T3/da active
-
2016
- 2016-05-18 HK HK16105678.0A patent/HK1217716A1/zh unknown
-
2018
- 2018-02-13 AU AU2018201039A patent/AU2018201039A1/en not_active Abandoned
- 2018-04-25 US US15/962,540 patent/US10906954B2/en active Active
- 2018-04-26 JP JP2018084885A patent/JP6664430B2/ja active Active
-
2019
- 2019-11-07 HR HRP20192013TT patent/HRP20192013T1/hr unknown
- 2019-11-13 CY CY20191101192T patent/CY1122463T1/el unknown
-
2020
- 2020-02-17 JP JP2020023936A patent/JP7149450B2/ja active Active
- 2020-03-25 AU AU2020202119A patent/AU2020202119B2/en active Active
- 2020-12-23 US US17/133,489 patent/US20210206829A1/en not_active Abandoned
-
2022
- 2022-11-25 AU AU2022275518A patent/AU2022275518A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1217716A1 (zh) | α- 融合蛋白處理 +疾病細胞 | |
| IL288256A (en) | Digital to biological converter | |
| HK1216647A1 (zh) | 治療性 抗體 | |
| HK1205759A1 (en) | Treatment of biomass | |
| BR112015013188A2 (pt) | método de fermentação otimizado | |
| PT2895071T (pt) | Biosensor implantável dado em forma de cabeça | |
| EP2906270A4 (en) | SYRINGE WITH SEVERAL COMPARTMENTS | |
| ZA201205425B (en) | Treatment with vb-201 | |
| GB201506603D0 (en) | Photobioreactor | |
| EP2937327A4 (en) | HFO-1234ZE AND HFC-245FA COPRODUCTION MANUFACTURING METHOD | |
| GB201309274D0 (en) | Treatment Of Fuel | |
| HUE037681T2 (hu) | Fermentálási eljárás | |
| ZA201405761B (en) | Pentose fermenting microoranisms | |
| EP2799403A4 (en) | TUBULAR DIGESTER | |
| GB201204645D0 (en) | Treatment of disease | |
| PL398028A1 (pl) | Fotobioreaktor | |
| GB201219431D0 (en) | Helix lift | |
| GB201211286D0 (en) | Novel biological factor | |
| GB201215621D0 (en) | Medical solution |